Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
Compass Pathways reported early results from its first Phase 3 trial of synthetic psilocybin (COMP360) for treatment‑resistant depression. In 258 patients, the 25 mg dose showed a statistically significant improvement versus placebo on the MADRS depression scale at week 6 (a 3.6‑point difference, p < 0.001). The Data and Safety…
This review explains how ketamine, a drug that blocks NMDA receptors, might work for people with treatment‑resistant depression. It says one injection of ketamine can rapidly reduce depressive symptoms, including acute suicidal behavior. The paper describes steps that could explain this: ketamine may raise glutamate, trigger growth of neuron branches,…
